Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss ...

Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing ...

Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clini ...

Scientists are developing dog weight loss drugs that work like Ozempic in humans, and they could be on the market as soon as ...

Vivani Medical ( ($VANI) ) has shared an update. On August 11, 2025, Vivani Medical entered into a Share Purchase Agreement to sell 7,936,507 ...

LIBERATE-1, the first-in-human application of Vivani’s NanoPortalTMimplant technology, showed a positive safety and tolerability profile, along with encouraging performance data for NPM-115 that met t ...

LIBERATE-1, the first-in-human application of Vivani’s NanoPortalTM implant technology, showed a positive safety and tolerability profile, along with ...

Vivani Medical announced that it brought in $10 million in equity financing as it progresses its drug delivery technology.

Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clini ...

How long should it take for Semaglutide to work? Semaglutide is the active ingredient in the weight loss medication Wegovy and the diabetes drugs Ozempic and Rybelsus, which are sometimes taken ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.